Domain Therapeutics S.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Domain Therapeutics S.A.
Domain To Bring First Wholly Owned GCPR Asset Into Clinic
The French firm is going it alone for the first time with a planned Phase I trial for its lead EP4 receptor antagonist in cancer after years of sharing its technology and GCPR expertise with big pharma.
Finance Watch: VC Mega-Rounds Are Alive And Well
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.
Deal Watch: Kite Inks Novel AML Target Discovery Tie-Up With HiFiBiO
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
Tech Transfer Roundup: GE Healthcare, Vanderbilt Partner To Optimize Precision Cancer Immunotherapy
Five-year collaboration will analyze data from thousands of cancer patients to optimize immunotherapy treatment and develop PET imaging tracers to stratify clinical trial participants. Also, MD Anderson starts 2019 with three new agreements.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Faust Pharmaceuticals
- Domain Therapeutics NA Inc.
- Kaldi Pharma
- Mavalon Therapeutics
- Neurofit SAS
- Prestwick Chemical SAS
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.